Semaglutide, injected once a week, has stronger hypoglycemic and weight loss effects, and has a lower risk of hypoglycemia
Birth control pills may not work as well while using Zepbound
Tesamorelin represents a significant advancement in growth hormone-releasing hormone analog development, emerging from the research laboratories of Theratechnologies, Inc
The BCBS FEP program, which covers federal employees, generally offers the most comprehensive weight loss medication coverage within the BCBS system
Tesamorelin has two Phase III lipodystrophy trials (LIPO-010 and CTR-1011), pooled analyses across 816 participants, the Stanley 2019 Lancet HIV NAFLD trial, the Stanley 2014 JAMA abdominal-fat trial, and mechanistic transcriptomic and proteomic follow-up papers